The Pharma Data

FEBRUARY 8, 2021

District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which lasts until October 2030. In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. glucosidase deficiency).

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

FEBRUARY 4, 2021

District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which lasts until October 2030. In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. glucosidase deficiency).

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

APRIL 27, 2021

District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which expire in October 2030. MRT5500 (SP0254), an mRNA vaccine candidate against SARS-CoV-2, entered Phase 1/2 to assess safety, immune response and reactogenicity. Interim results are expected in Q3 2021.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

JULY 11, 2021

Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi ® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers.

Immune Response 52

Immune Response Disease Vaccine Licensing 52